series-b
Stage
2
Investors
About
Mediar Therapeutics is a clinical-stage biotechnology company developing first-in-class antibody therapies designed to halt and reverse fibrosis by targeting key fibrotic mediator proteins that drive disease progression in chronically damaged organs.
Explore Mediar Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.